Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsNovartis AG ADR (NVS)
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.63
-3.85%
HEALTHCARE · Cap: $15.52M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 345736% more annual revenue ($56.58B vs $16.36M). NVS leads profitability with a 23.9% profit margin vs -4.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
HKPD
Avoid22
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+81.4%
Fair Value
$4.29
Current Price
$0.63
$3.67 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 3.0%
ROE of -13.4% — below average capital efficiency
Revenue declined 35.7%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : HKPD
The strongest argument for HKPD centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Operating Margin, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
HKPD profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 22/100), backed by strong 23.9% margins. HKPD offers better value entry with a 81.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other PHARMACEUTICAL RETAILERS Stocks
Want to dig deeper into these stocks?